Abstract
Mutational characterisation is described in newly diagnosed (ND) multiple myeloma (MM) but remains largely elusive for relapsed/refractory (RR) patients. Current practice for mutational characterisation is via analysis of DNA from single-site bone marrow (BM) biopsies, which is confounded by the known inter and intra-clonal spatial heterogeneity of the tumour(s). An alternative and more comprehensive approach is through the analysis of circulating cell-free (cf) tumour DNA (ctDNA) derived from the plasma (PL).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
